heart conditions News
-
Showcase
AARP Names Its Innovator in Aging Prize Winner
En español | A wristband that helps you cool off or warm up quickly, offering relief from hot flashes or increasing your comfort, won AARP’s Innovator in Aging prize Tuesday morning. AARP CEO Jo Ann Jenkins presented the award to the company, Embr Labs, for its Wave device during a live segment on Good Morning America. The advocacy group for older adults increasingly is looking to ...
By Aidar Health
-
Showcase
AARP Names Its Innovator in Aging Prize Winner
En español | A wristband that helps you cool off or warm up quickly, offering relief from hot flashes or increasing your comfort, won AARP’s Innovator in Aging prize Tuesday morning. AARP CEO Jo Ann Jenkins presented the award to the company, Embr Labs, for its Wave device during a live segment on Good Morning America. The advocacy group for older adults increasingly is looking to ...
By Aidar Health
-
Heat Shuts Down Chicago Marathon
CHICAGO, Illinois, October 8, 2007 (ENS) - One man died and hundreds of other people became ill as temperatures soared into the '80s during the 30th LaSalle Bank Chicago Marathon on Sunday. The race had nearly 36,000 starters from all 50 states and 120 countries. Temperatures were in the low 70s when the race began, but already had climbed into the 80s when the top runners were finishing. It ...
-
EPA Releases New PSA for American Heart Month
Today, the U.S. Environmental Protection Agency (EPA) issued a new Public Service Announcement (PSA) to educate the public and healthcare providers about the risks of air pollution to the heart. "Over more than four decades of EPA history, we've made tremendous progress cleaning up the air we breathe by using science to understand the harmful effects of air pollution," said EPA Administrator ...
-
Premier Inc. Awards BioSerenity Contract
BioSerenity, Inc., a leading global provider of diagnostic solutions in the areas of Sleep Medicine, Neurology, and Cardiology, announced today it has been awarded a group purchasing agreement for PP-SV-268 by Premier as part of its Preferred Partner agreement. The prevalence of sleep disorders, epilepsy and cardiovascular disease pose a significant challenge to the US healthcare system. ...
By BioSerenity
-
The CardiacSense medical watch receives the Israeli Ministry of Health’s regulatory approval
This is the first medical wristwatch to receive medical regulatory approval for beat by beat heart rate monitoring and A-Fib detection with ECG accuracy The approval allows the company to start selling its medical watch to patients in Israel requiring continuous heart rate monitoring. This enables early detection of Atrial Fibrillation, which can cause severe heart problems, strokes and ...
By CardiacSense
-
Hot Tub and Spa Safety Checklist
Spas and Hot Tubs can be very relaxing during the cooler seasons, but like anything else you have to consider safety so that your fun time isn’t ruined by an avoidable accident. Here are a few tips to safely enjoy your Spa or Hot Tub That’s HOT – Temperatures above 104°F can raise your body’s internal temperature to dangerous levels. Overheating could cause you to ...
By Sutro
-
HSC Partners with CardiacSense for medical-grade wearables
CardiacSense is a leading manufacturer of a range of wearable devices for the continuous monitoring of heart arrhythmias and blood pressure HSC signs exclusive Distribution Agreement for Australia & New Zealand for watches & wristbands HomeStay to integrate CardiacSense solutions in HSC’s IoT Platform for assistive technology HomeStay Care Limited (ASX: HSC) ...
By CardiacSense
-
Robocath successfully carries out Europe’s first remote robotic-assisted coronary angioplasty
Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces the successful completion of the first remote robotic-assisted coronary angioplasty in Europe. The procedure was carried out by Prof. Eric Durand and Prof. Rémi Sabatier at the Rouen Medical Training Center and Caen University Hospital in ...
By Robocath
-
Daxor Awarded New Patent for Blood Volume Guidance Technology to Improve Treatment & Outcomes
Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced that the United States Patent and Trademark Office has issued the company a new patent (U.S. Patent No. 11,204,356 B2) that protects a proprietary clinical guidance system for volume management utilizing unique volume metrics combined with treatment pathways. “We are very excited ...
-
Kohl`s department stores awards $10,000 scholarships to 10 outstanding young volunteers
Today, Kohl"s Department Stores (NYSE: KSS) named 10 outstanding young volunteers as national winners of the Kohl"s Kids Who Care Scholarship Program. As Kohl"s celebrates 10 years of rewarding stand-up kids through the program, the company has increased its 2010 national scholarship totals to $10,000 per winner. In addition to recognizing these volunteers, ranging in age from nine to 18, with ...
-
Analysis of the cryolipolysis slimming machine advantages and disadvantages
Cryolipolysis is a medical aesthetic technique that uses freezing to break down excess fat in the body to achieve a slimming effect. This technique has a great popularity and many people feel confident and beautiful because of the success of this technique to lose weight. As we all know, the medical aesthetic industry has always been a hot industry and cryolipolysis beauty machine as a technique ...
-
Professor Gust H. Bardy, M.D. of Bardy Diagnostics Partners with Arrhythmia Alliance to Increase Patient Awareness of Heart Arrhythmias and Early Detection
(Seattle, WA – November 17, 2020) – Chief Medical Officer of Bardy Diagnostics and Clinical Professor of Medicine University of Washington Professor Gust H. Bardy sat down with Trudie Lobban, MBE, Founder and CEO of Arrhythmia Alliance, a non-profit organization dedicated to improving the diagnosis, treatment, and quality of life for all those affected by arrhythmias, to discuss the ...
-
Critical Diagnostics Inks Exclusive Worldwide License Agreement for New Heart Failure Biomarker sNEP
Critical Diagnostics announced today that it entered into a license agreement for the exclusive worldwide rights to the use of the biomarker soluble neprilysin (sNEP) in the diagnosis and monitoring of heart failure patients. Health Sciences Research Institute Germans Trias i Pujol Foundation (IGTP) of Barcelona Spain is the licensor. The neprilysin inhibitor Sacubitril is a key ingredient in a ...
-
Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh will present a corporate overview at the H.C. Wainwright BioConnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022. Mr. Feldshuh will provide company updates and key highlights, including a new patent award and progress ...
-
CVRx Receives MR-Conditional Labeling Approval for its Barostim Heart Failure System
MINNEAPOLIS, MAY 9,2022 - CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), developer of the world's first FDA-approved neuromodulation device to treat the symptoms of heart failure, has received U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR) conditional labeling for its Barostim System. The Barostim System now includes instructions to allow for safe MRI scans of the head and ...
By CVRx
-
NHS Long Term Plan gives thousands of life changing diabetes monitors
Nearly 30,000 people across the country with Type 1 diabetes have received life-changing diabetes monitors through the NHS Long Term Plan. The innovative device, which is the size of a £2 coin and worn on the arm, means people with Type 1 do not have to carry out multiple painful finger-prick checks to monitor their blood sugar levels. Instead, people with the condition can monitor their ...
-
Ancora Heart Announces Expansion of U.S. Early Feasibility Study
Santa Clara, Calif.– February 3, 2020 – Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of enrollment in its CorCinch HFrEF Early Feasibility Study (EFS), which is evaluating the AccuCinch® Ventricular Repair System in patients with reduced ejection ...
-
Ancora Heart Receives IDE Approval for CorCinch-HF Pivotal Study of the AccuCinch Ventricular Restoration System
Santa Clara, Calif.– June 30, 2020 – Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application for the CorCinch-HF pivotal study, which is designed to evaluate the safety and efficacy of the AccuCinch® Ventricular Restoration System in ...
-
CVRx Announces First Clinical Procedure with a New Ultrasound-Guided Implant Approach, the Latest Advancement in Barostim™ for the Treatment of Heart Failure Symptoms
MINNEAPOLIS, June 10, 2021 - CVRx©. developer of the world's first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF). announced the completion of the first clinical procedure with the company's new lead implantation approach. The novel ultrasound-guided technique is the latest advancement of CVRx's Barostim™ Baroreflex Activation Therapy (BAT™) to ...
By CVRx
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you